MAY 03, 2018 08:00 AM PDT

Fecal Lactoferrin Measurements in Clinical Practice

C.E. CREDITS: CME | P.A.C.E. CE | Florida CE
Speakers
  • Assistant Professor of Pediatrics, Harvard Medical School and Program Director, HMS Fellowship in Pediatric Gastroenterology, Boston Children's Hospital
    Biography
      Dr. Paul Rufo is an Assistant Professor of Pediatrics at Harvard Medical School and the Program Director of the Harvard Medical School Fellowship in Pediatric Gastroenterology and Hepatology at Boston Children's Hospital. He is a Senior Associate in the Center for Inflammatory Bowel at Boston Children's Hospital and is affiliated with Beth Israel Deaconness Medical Center and Brigham & Women's Hospital. His research is focused on the development of new modalities for use in the diagnosis and interval assessment of children and adults with IBD. His research also invovled the development of new therapies for inflammatory bowel disease, as well as quality assurance initiaites in this patient population. Dr. Rufo received his medical degree from the University of Massachusetts Medical School and an MMSc degree from Harvard Medical School.

    Abstract:

    DATE:  May 3rd, 2018

    TIME:   8:00 AM PDT, 11:00 AM EDT

    Intestinal inflammation is a hallmark of the inflammatory bowel diseases (IBD), including ulcerative colitis and Crohn's disease.  These chronic autoimmune GI illnesses affect upwards of 3 million children and adults in the United States.  Many of the symptoms in patients with IBD overlap with those observed in patients with irritable bowel syndrome (IBS), a discrete and likely pathogenically pleomorphic gastrointestinal illness. Nonetheless, there is a premium on making a distinction between IBD and IBS as their treatment differs significantly.  Fecal lactoferrin testing is a non-invasive metric that can be used to help differentiate patients presenting with non-specific gastrointestinal symptoms as having either IBD or IBS.  Previous data have demonstrated that fecal lactoferrin levels may also useful in tracking disease activity or assessing response to therapy.  Several factors make lactoferrin a particularly useful biomarker:  it is structurally stable and not sensitive to bacterial proteases in the intestinal lumen, it has a steady baseline with well-defined clinical cutoffs, and has broad applicability as it is reliable in virtually any scenario in which a clinician is trying to discern if a particular patient is presenting with an infectious, autoimmune, or inflammatory gastrointestinal disease. These attributes can be leveraged to provide improve health outcomes while decreasing the economic burden on the healthcare system.

    Learning Objectives:

    • Identify scenarios in which fecal lactoferrin testing may aid in diagnosis
    • Recognize when fecal lactoferrin levels may be useful in tracking disease activity or assessing response to therapy
    • Use fecal lactoferrin biomarkers as a first-step diagnostic strategy to minimize the need for scoping on certain patient populations, like pediatrics, for whom a more non-invasive diagnostic tool is beneficial

    This webinar has been approved for Continuing Education credits.  Please see the following link for more information about the CME credits being provided; CME Credits


    Show Resources
    You May Also Like
    MAY 24, 2018 09:30 AM PDT
    C.E. CREDITS
    MAY 24, 2018 09:30 AM PDT
    DATE: May 24, 2018 TIME: 9:30PM PDT The current gold standard in in vitro pre-clinical cancer treatment screening remain cell lines,...
    APR 27, 2018 10:00 AM PDT
    C.E. CREDITS
    APR 27, 2018 10:00 AM PDT
    DATE: April 27, 2018TIME: 10:00am PST, 1:00pm ESTGlioblastoma (GBM) and Medulloblastoma (MB) are the most common adult and paediatric brain tumours, both of which can have devastating c...
    AUG 15, 2018 08:00 AM PDT
    C.E. CREDITS
    AUG 15, 2018 08:00 AM PDT
    DATE: August 15, 2018TIME: 08:00AM PDT, 11:00AM EDTThe failure of current chemotherapeutic strategies in the fight against cancer can be largely attributed to the occurrence of drug res...
    JUN 20, 2018 10:00 AM EDT
    C.E. CREDITS
    JUN 20, 2018 10:00 AM EDT
    DATE: June 20, 2018TIME: 07:00AM PDT, 10:00AM EDTIntroducing GE’s New Lyo-StableTM service. Sepsis is one of the top challenges facing hospitals in terms of clinical outcomes...
    JUN 26, 2018 06:00 AM PDT
    C.E. CREDITS
    JUN 26, 2018 06:00 AM PDT
    Date: June 26, 2018Time: 6:00 a.m. PDT, 9:00 a.m. EDT, 1500 CEST Today’s hematology analyzers employ various methods for enumerating platelets. These methods include: e...
    MAY 22, 2018 08:00 AM PDT
    C.E. CREDITS
    MAY 22, 2018 08:00 AM PDT
    DATE: May 22, 2018TIME: 08:00AM PDT The nuclear receptors pregnane X receptor (PXR) and constitutive androstane receptor (CAR) are closely related transcription factors that...
    Loading Comments...